A melanoma vaccine built from the patient's own tumour
A phase 3 trial called INTerpath-001 randomised 1,137 adults whose melanoma, stage IIB to IV, had been completely cut out, across 157 centres. Everyone got pembrolizumab, the immunotherapy already used after surgery.
Two out of three also got intismeran autogene, a vaccine made from the mutations in that person's own removed tumour; the rest got a placebo. At a median follow-up of 24.6 months, the vaccine group had a 42 percent lower risk of recurrence or death (hazard ratio 0.58, 95 percent confidence interval 0.45 to 0.75). At two years, 82.2 percent were alive and cancer-free, against 70.0 percent on pembrolizumab alone. The risk of distant spread or death fell 38 percent, with 88.5 percent versus 80.2 percent free of distant metastasis at two years 113. Georgina V. Long of the Melanoma Institute Australia presented the data at the European Society for Medical Oncology meeting in Madrid on 24 October 113108.